Shattuck Labs(US:STTK) Yahoo Finance·2025-11-29 06:26Core Viewpoint - Shattuck Labs, Inc. (NASDAQ:STTK) is recognized for its strong performance and potential upside, making it a notable investment opportunity among penny stocks [1]. Financial Performance - For Q3 2025, Shattuck Labs reported a net loss of $10.1 million, equating to $0.14 per basic and diluted share [3]. - Research and Development (R&D) expenses decreased to $7.60 million, while General and Administrative (G&A) expenses totaled $4.10 million [3]. - The company maintains a solid financial position with cash and investments amounting to $86.10 million [2]. Drug Development Progress - The Phase 1 readout for the SL-325 drug is anticipated in Q2 2026, which is viewed as a significant growth catalyst [2]. - The company is advancing the SL-325 trial and is making progress towards selecting a bispecific candidate for development in 2026 [3]. - The SL-325 drug targets the DR3/TL1A pathway, aiming for a complete blockade, indicating its potential in treating autoimmune and inflammatory diseases [4]. Analyst Sentiment - Analyst Joseph Pantginis from H.C. Wainwright has reiterated a "Hold" rating on Shattuck Labs, citing the drug's clinical potential and the company's balanced risk profile [2].